Evolent Health (EVH) – Analysts’ Weekly Ratings Changes

Several analysts have recently updated their ratings and price targets for Evolent Health (NYSE: EVH):

• 12/8/2025 – Evolent Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/2/2025 – Evolent Health was given a new $6.00 price target on by analysts at Piper Sandler.
• 12/1/2025 – Evolent Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Evolent Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/21/2025 – Evolent Health had its price target lowered by analysts at Citigroup Inc. from $11.50 to $9.50. They now have a “buy” rating on the stock.
• 11/19/2025 – Evolent Health had its “sell (e+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/17/2025 – Evolent Health had its price target lowered by analysts at JPMorgan Chase & Co. from $13.00 to $7.00. They now have an “overweight” rating on the stock.
• 11/14/2025 – Evolent Health had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $9.00. They now have a “buy” rating on the stock.
• 11/13/2025 – Evolent Health was upgraded by analysts at Stephens from an “equal weight” rating to an “overweight” rating. They now have a $7.00 price target on the stock.
• 11/13/2025 – Evolent Health is now covered by analysts at BMO Capital Markets. They set an “outperform” rating and a $7.00 price target on the stock.
• 11/12/2025 – Evolent Health had its price target lowered by analysts at Oppenheimer Holdings, Inc. from $18.00 to $12.00. They now have an “outperform” rating on the stock.
• 11/10/2025 – Evolent Health was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating.
• 11/10/2025 – Evolent Health had its price target lowered by analysts at Truist Financial Corporation from $16.00 to $10.00. They now have a “buy” rating on the stock.
• 11/10/2025 – Evolent Health had its price target lowered by analysts at Citizens Jmp from $13.00 to $11.00. They now have a “market outperform” rating on the stock.
• 11/7/2025 – Evolent Health had its price target lowered by analysts at BTIG Research from $20.00 to $16.00. They now have a “buy” rating on the stock.

Insider Activity at Evolent Health

In other Evolent Health news, Director Brendan B. Springstubb bought 10,000 shares of Evolent Health stock in a transaction on Tuesday, November 18th. The shares were purchased at an average cost of $3.82 per share, for a total transaction of $38,200.00. Following the completion of the acquisition, the director owned 58,821 shares in the company, valued at approximately $224,696.22. The trade was a 20.48% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. 1.40% of the stock is currently owned by corporate insiders.

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.